Filter

Refine by date

—
  • Print
  • Save
  • Print

Diagnosis and Treatment > Investigation > Cardiac index

You are looking at 1 - 1 of 1 items

Kun Zhang Department of Cardiology and Angiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Kun Zhang in
Google Scholar
PubMed Close
,
Lukas J Lehner Department of Nephrology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Lukas J Lehner in
Google Scholar
PubMed Close
,
Damaris Praeger Department of Cardiology and Angiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Damaris Praeger in
Google Scholar
PubMed Close
,
Gert Baumann Department of Cardiology and Angiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Gert Baumann in
Google Scholar
PubMed Close
,
Fabian Knebel Department of Cardiology and Angiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Fabian Knebel in
Google Scholar
PubMed Close
,
Marcus Quinkler Department of Endocrinology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Marcus Quinkler in
Google Scholar
PubMed Close
, and
Torsten K Roepke Department of Cardiology and Angiology, Charité – Universitätsmedizin Berlin, Charitéplatz 1, 10115 Berlin, Germany

Search for other papers by Torsten K Roepke in
Google Scholar
PubMed Close

Summary

Neuroendocrine tumours (NETs) represent a broad spectrum of tumours, of which the serotonin-producing carcinoid is the most common and has been shown to cause right ventricular heart failure. However, an association between heart failure and NETs other than carcinoid has not been established so far. In this case report, we describe a 51-year-old patient with a glucagon-producing NET of the pancreas who developed acute heart failure and even cardiogenic shock despite therapy. Heart failure eventually regressed after initialising i.v. treatment with the somatostatin analogue octreotide. Chromogranin A as a tumour marker was shown to be significantly elevated, and it decreased with clinical improvement of the patient. The effects of long-time stimulation of glucagon on the myocardium have not been studied yet; however, sarcoplasmic reticulum calcium leak can be discussed as a possible mechanism for glucagon-induced heart failure.

Learning points

  • Glucagonoma can be a cause for heart failure.

  • i.v. infusion of octreotide can be successfully used to treat glucagonoma-induced acute heart failure.

  • We suggest that cardiac function should be monitored in all NET patients.

Taxonomy:
Clinical Overview, Gland/Organ, Heart, Pancreas, Topic, Cardiovascular endocrinology, Hormone, Glucagon, Condition/ Syndrome, Glucagonoma, MEN1, Neuroendocrine tumour, Patient Demographics, Age, Adult, Gender, Female, Ethnicity, White, Country of Treatment, Germany, Diagnosis and Treatment, Signs and Symptoms, Cardiogenic shock, Coughing, Dyspnoea, Heart failure, Hypotension, Tachycardia, Investigation, Cardiac index, Chromogranin A, Echocardiogram, Myocardial biopsy, Systemic vascular resistance index, Medication, Everolimus, Octreotide, Somatostatin analogues, Related Disciplines, Cardiology, Publication Details, Case Report Type, Unique/unexpected symptoms or presentations of a disease
DOI:
https://doi.org/10.1530/EDM-14-0061
Volume/Issue:
Volume 2014: Issue 1
Open access